New Report Finds Cancer Drugs Account for Over a Quarter of All New Drug Approvals in the United States
Cancer drugs currently account for 27% of all new drug approvals in the United States since 2010—an increase from the 4% share they occupied in the 1980s, a newly completed analysis summarized in the most recent issue of the Tufts CSDD Impact Report.
From 1980 through 2018, the U.S. Food and Drug Administration (FDA) approved a total of 126 cancer drugs to treat solid and hematologic tumors.
The analysis also found:
- Clinical development time for cancer drug approvals during 1999–2018 was 9% longer compared to noncancer drugs
- Regulatory approval phase time for cancer approvals during 1999–2018 was 48% shorter on average vs noncancer approvals
- Total clinical development and approval phase times during 1999–2018 was 17% longer on average for hematologic drugs (8.8 years) compared to drugs for solid tumors (7.5 years)
- Substantially higher percentages of new cancer drug approvals received priority ratings from the FDA and had orphan drug status during 1999–2018 compared to new noncancer drug approvals.
“New approaches to development helped to drive the surge in new oncology products, including improvements in clinical trial design, novel drug formats, and a focus on new and validated targets.”— Joseph A. DiMasi, PhD
Tweet this quote
“New approaches to development helped to drive the surge in new oncology products, including improvements in clinical trial design, novel drug formats, and a focus on new and validated targets,” said Joseph A. DiMasi, PhD, Research Associate Professor and Director of Economic Analysis at Tufts Center for the Study of Drug Development, who conducted the analysis. “Those efforts appear to have paid off, as [patients with] cancer today have many more effective treatment options.”
He noted that pressure for still more oncology drugs is likely to continue to address currently untreatable or inadequately treated cancers.
“Developers will be challenged to control development costs—particularly those tied to recruiting sufficient numbers of patients for clinical trials involving rare cancers—and manage payer pressure to control drug prices and contain pharmaceutical spending in the U.S.,” Dr. DiMasi concluded.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.